^
    Back
    Association details:
    Biomarker:BRAF V600E + BRAF K601_W604del
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Genet
    Title:

    Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer

    Published date:
    05/10/2022
    Excerpt:
    We examined 16 BRAF tumors with p.V600E-positive non-small-cell lung cancer….One patient (6.2%) had a BRAF p.V600E and p.K601_W604 compound mutation with a good clinical response to dabrafenib and trametinib.
    DOI:
    10.1016/j.cancergen.2022.05.00